These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36647763)

  • 1. Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.
    Su W; Tan M; Wang Z; Zhang J; Huang W; Song H; Wang X; Ran H; Gao Y; Nie G; Wang H
    Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202218128. PubMed ID: 36647763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
    Ren X; Wang L; Liu L; Liu J
    Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
    Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
    J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.
    Wang Z; Tan M; Su W; Huang W; Zhang J; Jia F; Cao G; Liu X; Song H; Ran H; Nie G; Wang H
    J Med Chem; 2023 May; 66(9):6263-6273. PubMed ID: 37092695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
    Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
    Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 degradation pathway and immunotherapy for cancer.
    Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
    Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1.
    Cotton AD; Nguyen DP; Gramespacher JA; Seiple IB; Wells JA
    J Am Chem Soc; 2021 Jan; 143(2):593-598. PubMed ID: 33395526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACs: Novel approach for cancer breakdown by breaking proteins.
    Memon H; Patel BM
    Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: Novel tools for improving immunotherapy in cancer.
    Li S; Chen T; Liu J; Zhang H; Li J; Wang Z; Shang G
    Cancer Lett; 2023 Apr; 560():216128. PubMed ID: 36933781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
    Yuan J; Li J; Shang M; Fu Y; Wang T
    Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation.
    Sun R; Meng Z; Lee H; Offringa R; Niehrs C
    Cell Chem Biol; 2023 Jul; 30(7):739-752.e8. PubMed ID: 37321224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments of PROTACs technology in immune-related diseases.
    Wang C; Zhang Y; Deng J; Liang B; Xing D
    Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.